A Bayesian network meta-analysis comparing concurrent chemoradiotherapy followed by adjuvant chemotherapy, concurrent chemoradiotherapy alone and radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma

Annals of Oncology

Volumn 26, Issue 1, 2015, Pages 205-211

  Chen, Y P ^a   Wang, Z X ^b   Chen, L ^a   Liu, X ^a   Tang, L L ^a   Mao, Y P ^a   Li, W F ^a   Lin, A H ^c   Sun, Y ^a   Ma, Jun ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

Adjuvant chemotherapy; Concurrent chemoradiotherapy; Nasopharyngeal carcinoma; Network meta analysis; Radiotherapy

Indexed keywords

ADVANCED CANCER; ARTICLE; BAYES THEOREM; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL (TOPIC); DISTANT METASTASIS FREE SURVIVAL; HAZARD RATIO; HUMAN; INTERMETHOD COMPARISON; LOCAL RECURRENCE FREE SURVIVAL; META ANALYSIS; NASOPHARYNX CARCINOMA; OVERALL SURVIVAL; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; MORTALITY; NASOPHARYNGEAL NEOPLASMS;

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BAYES THEOREM; CHEMORADIOTHERAPY; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; HUMANS; NASOPHARYNGEAL NEOPLASMS;

EID: 84922565381     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu507     Document Type: Article

References (27)

1. Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet 2005; 365: 2041-2054.
2. Ma J, Mai HQ, Hong MH et al. Is the 1997 AJCC staging system for nasopharyngeal carcinoma prognostically useful for Chinese patient populations? Int J Radiat Oncol Biol Phys 2001; 50: 1181-1189.
3. Zhang L, Zhao C, Ghimire B et al. The role of concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma among endemic population: a meta-analysis of the phase III randomized trials. BMC Cancer 2010; 10: 558.
4. OuYang PY, Xie C, Mao YP et al. Significant efficacies of neoadjuvant and adjuvant chemotherapy for nasopharyngeal carcinoma by meta-analysis of published literature-based randomized, controlled trials. Ann Oncol 2013; 24: 2136-2146.
5. Al-Sarraf M, LeBlanc M, Giri PG et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998; 16: 1310-1317.
6. Kwong DL, Sham JS, Au GK et al. Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study. J Clin Oncol 2004; 22: 2643-2653.
7. Wee J, Tan EH, Tai BC et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol 2005; 23: 6730-6738.
8. Lee AW, Lau WH, Tung SY et al. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol 2005; 23: 6966-6975.
9. Lee AW, Tung SY, Chua DT et al. Randomized trial of radiotherapy plus concurrentadjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 2010; 102: 1188-1198.
10. Lee AW, Tung SY, Chan AT et al. Preliminary results of a randomized study (NPC-9902 Trial) on therapeutic gain by concurrent chemotherapy and/or accelerated fractionation for locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2006; 66: 142-151.
11. Lee AW, Tung SY, Chan AT et al. A randomized trial on addition of concurrentadjuvant chemotherapy and/or accelerated fractionation for locally-advanced nasopharyngeal carcinoma. Radiother Oncol 2011; 98: 15-22.
12. Chen Y, Liu MZ, Liang SB et al. Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of china. Int J Radiat Oncol Biol Phys 2008; 71: 1356-1364.
13. Chen Y, Sun Y, Liang SB et al. Progress report of a randomized trial comparing long-term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVB nasopharyngeal carcinoma from endemic regions of China. Cancer 2013; 119: 2230-2238.
14. Chen L, Hu CS, Chen XZ et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol 2012; 13: 163-171.
15. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform metaanalyses of the published literature for survival endpoints. Stat Med 1998; 17: 2815-2834.
16. Chen QY, Wen YF, Guo L et al. Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial. J Natl Cancer Inst 2011; 103: 1761-1770.
17. Lin JC, Jan JS, Hsu CY et al. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol 2003; 21: 631-637.
18. Baujat B, Audry H, Bourhis J et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys 2006; 64: 47-56.
19. Chan AT, Teo PM, Ngan RK et al. Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol 2002; 20: 2038-2044.
20. Chan AT, Leung SF, Ngan RK et al. Overall survival after concurrent cisplatinradiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 2005; 97: 536-539.
21. Zhang L, Zhao C, Peng PJ et al. Phase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: preliminary results. J Clin Oncol 2005; 23: 8461-8468.
22. Wu X, Huang PY, Peng PJ et al. Long-term follow-up of a phase III study comparing radiotherapy with or without weekly oxaliplatin for locoregionally advanced nasopharyngeal carcinoma. Ann Oncol 2013; 24: 2131-2136.
23. Blanchard P, Hill C, Guihenneuc-Jouyaux C et al. Mixed treatment comparison meta-analysis of altered fractionated radiotherapy and chemotherapy in head and neck cancer. J Clin Epidemiol 2011; 64: 985-992.
24. Jacobs C, Lyman G, Velez-Garcia E et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992; 10: 257-263.
25. Chan AT, Gregoire V, Lefebvre JL et al. Nasopharyngeal cancer: EHNS-ESMOESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23(Suppl 7): vii83-85.
26. Cheng SH, Tsai SY, Yen KL et al. Prognostic significance of parapharyngeal space venous plexus and marrow involvement: potential landmarks of dissemination for stage I-III nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2005; 61: 456-465.
27. Leung SF, Chan KC, Ma BB et al. Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma. Ann Oncol 2014; 25: 1204-1208.